Jupiter Neurosciences wins exclusive U.S. rights to ALA-002

Jupiter Neurosciences has signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based candidate with FDA Novel Chemical Entity status. The deal could be worth up to $100 million and gives the company a second clinical-stage CNS program alongside its Parkinson’s pipeline.

Why it matters: - Jupiter Neurosciences is moving from a single-program company to a dual clinical-stage central nervous system developer. - The ALA-002 deal adds a second development track alongside Jupiter’s Parkinson’s disease program. - The agreement gives Jupiter perpetual exclusive U.S. rights to a candidate with FDA Novel Chemical Entity designation and potential regulatory exclusivity benefits. - The transaction could also create a long-term U.S. commercialization opportunity if ALA-002 reaches approval and sales milestones.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings for ALA-002. - The agreement covers perpetual exclusive U.S. rights to the asset. - Jupiter said the transaction has a potential value of up to $100 million, including milestone payments. - The announcement was made July 22, 2026.

The details: - Jupiter will pay $3.3 million upfront, split between $1.5 million in cash and $1.8 million in JUNS common stock. - The stock portion carries a 120-day lock-up. - A $3.3 million development milestone is due upon Phase 3 first patient in. - A $20 million regulatory milestone is due upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when cumulative U.S. net sales reach $333 million, $1 billion and $2 billion. - PharmAla is entitled to a 3% royalty on net sales after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation. - The FDA has designated ALA-002 as a Novel Chemical Entity. - The NCE status provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - Jupiter said ALA-002 was engineered to improve cardiovascular safety and reduce abuse liability compared with racemic MDMA while preserving pro-social and therapeutic properties. - PharmAla’s MDMA supply is active in U.S. government-sponsored VA and DHA clinical trials. - The addressable U.S. psychedelic therapeutics market is estimated at $3 billion in 2024 and $8 billion by 2030, according to Strategic Market Research. - PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms to be negotiated. - The manufacturing arrangement is intended to accelerate Jupiter’s development timeline. - Jupiter’s lead program is JOTROL, a proprietary enhanced-bioavailability resveratrol formulation now in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement.

Between the lines: - The deal gives Jupiter exposure to the psychedelic medicine market while keeping its existing neurodegeneration program in play. - The company is positioning ALA-002 as a differentiated asset with a clearer U.S. path because of its FDA NCE status. - Management is also aligning the transaction with a more favorable U.S. regulatory backdrop for investigational psychedelic therapies. - The press release points to President Donald J. Trump’s April 18, 2026 executive order on serious mental illness as a possible catalyst for faster review and access pathways. - Jupiter said the order includes a Right to Try pathway, Commissioner's National Priority Vouchers and $50 million in federal ARPA-H funding. - The strategic case rests on diversification, but the asset remains early-stage and subject to clinical, regulatory and financing risk.

What’s next: - Jupiter plans to advance both its Parkinson’s program and ALA-002 toward clinical and regulatory milestones. - PharmAla will continue supplying the drug product while commercial terms are negotiated. - Jupiter expects the next 12 months to be transformative, according to President and Chief Business Officer Alison Silva. - Future value depends on clinical execution, regulatory progress and eventual commercialization in the United States.

The bottom line: - Jupiter has added a second clinical-stage CNS asset with meaningful milestone potential, but the company still has to prove ALA-002 in the clinic and navigate a long regulatory path.